LIVE
13,654 Events in DB FDA 29 reg. actions today EMA 2,182 entries tracked Health Canada 11,234 entries ANVISA 24 entries 4 Regulatory Bodies · 1 Pipeline UUID-Stable · EU-Hosted · GDPR Updated daily at 07:30 UTC 13,654 Events in DB FDA 29 reg. actions today EMA 2,182 entries tracked Health Canada 11,234 entries ANVISA 24 entries 4 Regulatory Bodies · 1 Pipeline UUID-Stable · EU-Hosted · GDPR Updated daily at 07:30 UTC
BRUNOSAN BIOTECH INTELLIGENCE

Daily intelligence.
Four regulators.
One pipeline.

Every FDA approval, EMA filing, Health Canada entry, and ANVISA action — tracked simultaneously. No other free source compiles this cross-regulatory view.

— Total Events in DB Cumulative pipeline
29 FDA Reg. Actions Approvals + filings + rejections
2,182 EMA Entries In BrunoSan DB
11,234 Health Canada DPD integration
24 ANVISA Entries Brazil regulatory
0.90 Avg. Confidence Source-verified
🇺🇸 FDA
U.S. Food & Drug Administration
New Drug Applications, Biologics License, IND holds, Complete Response Letters
29
reg. actions tracked today
🇪🇺 EMA
European Medicines Agency
CHMP opinions, centralized approvals, EPAR database, orphan designations
2,182
entries in BrunoSan DB
🇨🇦 Health Canada
Health Canada DPD
Drug Product Database — full historic approval records, NOC/NOC-c, DIN registry
11,234
DPD entries integrated
🇧🇷 ANVISA
ANVISA Brazil
Brazilian Health Surveillance Agency — RDC resolutions, drug registrations, market authorizations
24
actions tracked today
🧬
Cross-Regulatory Status Per DrugFDA + EMA + HC + ANVISA in one view. No free source does this.
📡
UUID-Stable ObjectsEvery event has a deterministic ID. Same drug = same UUID. Always.
⚡
Daily Pipeline at 07:30 UTCAP0→AP6 runs every morning. Articles + images generated automatically.
🔌
MCP-NativePlug directly into Claude, GPT, or any agent. Get API access →
Intelligence Articles
Latest Biotech Signals
Generated daily from 13,654 tracked events · Pipeline pull: loading...
FDA Approval Global Signal 2026-04-02
Lilly's oral GLP-1 Foundayo (orforglipron) approved for weight loss, challenging market leaders
Eli Lilly · Foundayo (orforglipron)
FDA approved the once-daily pill, which can be taken without food or water restrictions. The highest dose led to an average weight loss of 27 pounds in the ATTAIN-1 trial.
Confidence: 0.90 Read article →
Phase 3 Flash Alert 2026-04-02
AstraZeneca's Strensiq successor fails Phase 3 trial for rare metabolic disease
AstraZeneca · Strensiq successor (unnamed)
The Phase 3 trial failed to meet its primary endpoint, casting doubt on plans to expand its market reach.
Confidence: 0.90 Read article →
FDA Rejection Flash Alert 2026-04-02
Novo Nordisk lays off 400 at Indiana plant following multiple FDA rejections for client drugs
Novo Nordisk · N/A (Manufacturing Facility)
Layoffs follow FDA rejections for drugs from three different companies manufactured at the facility, citing manufacturing issues.
Confidence: 0.90 Read article →
Trial Halt Global Signal 2026-04-02
Gilead terminates mid-stage HIV trial amid ongoing FDA clinical hold
Gilead Sciences · Next-gen HIV drug (unnamed)
The company terminated a mid-stage HIV trial, with an FDA clinical hold on two of its next-gen HIV drugs remaining in place since last June.
Confidence: 0.90 Read article →
Phase 3 Global Signal 2026-04-02
Precision immunotherapy shows promise in sepsis, improving organ dysfunction in Phase 3 trial
N/A (ImmunoSep trial) · Precision immunotherapy (unnamed)
Confidence: 0.90 Read article →